OTEZLA is indicated for the treatment of moderate to severe chronic Plaque Psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). For treatment of Plaque Psoriasis in Sweden, OTEZLA is reimbursed according to indication.
OTEZLA, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active Psoriatic Arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. For treatment of active Psoriatic Arthritis in Sweden, OTEZLA is reimbursed according to indication, but with the limitation only in monotherapy.
Welcome to the OTEZLA® website
This site is intended for physicians and other healthcare professionals. Please select a designation below so we can direct you to the appropriate landing page.